Sanofi-a Ventis Deutschland Gmbh

Rheinische Friedrich-wilhelms-universitat Bonn

Evi Kostenis

Detlef Kozian

Sylvain Ricard

Sandrine Mace

Jean-Francois Deleuze

Karl-Ernst Siegler

Johann Gassenhuber

Martina Jacobs

Rhalid Akkari

Christa Muller

Andreas Spinrath

Stephanie Hennen

Lucas Peters

Younis Baqi

Kirsten Ritter

Paulus Wohlfart

Jochen Huber

Andreas Busch

Christa E Müller

Vera Regitz-Zagrosek

Kai Rosport

Andreas Bueltmann

Christine Baumgartner

Götz Muench

Martin Ungerer

The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

GPR 17 agonists and screening assay

Methods of identifying modulators of GPR17

The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.

Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof

The invention relates to a method for identifying a compound which stimulates or attenuates the activity of the G protein-coupled receptor mas-like 1.

Method for identifying agonists or antagonists of the G-protein coupled receptor mas-like 1

The invention relates to a widely applicable process for identifying chemical compounds, which modulate G-protein-coupled receptors, by means of novel hybrid G-proteins with broad receptor specificity and very high expression and also to chemical compounds which can be identified by such a process.

Process for identifying modulators of G-protein-coupled receptors

The invention relates to a method for identifying a compound which modifies the activity of the urotensin II receptor, with genes or gene products which are involved in the structure, formation or breakdown of the extracellular matrix being influenced.

Method for identifying compounds for treating aging processes in the coronary circulatory system

Embodiments of the present invention relate to methods for identifying compounds which modify the activity of the G protein-coupled receptor GPR45 like/GPR63, compositions useful for this method, and compounds identified by it.

Method for identifying agonists and antagonists of the GPR45-like/GPR63 receptor

Mammals and myocardial mammal cells transformed with G protein coupled receptor EDG2 are presented for use in an animal model for heart failure.

Use of EDG2 receptor in an animal model of heart failure

The present invention relates to newly identified human EDG8 receptors, polynucleotides encoding this receptor, polypeptides encoded by such polynucleotides, the preparation and the use of such polynucleotides and polypeptides.

EDG8 receptor, its preparation and use

Growing community of inventors

Grebenau, Germany

Evi Kostenis